Epizyme (EPZM) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Tech selloff weighs down Wall Street as bond yields climb
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Epizyme (EPZM) PT Raised to $24 at Wedbush
March 14, 2018 6:27 AM EDTWedbush raised its price target on Epizyme (NASDAQ: EPZM) to $24.00 (from $21.00) while maintaining a Outperform rating.
Analyst David Nierengarten commented, "We are increasing our PT to $24 (from $21) as we incorporate the tazemetostat opportunity in mesothelioma into our model, and update our... More
Epizyme (EPZM) PT Raised to $30 at Citi Citing 'Multiple Avenues for Upside'
March 14, 2018 4:43 AM EDTCiti raised its price target on Epizyme (NASDAQ: EPZM) to $30.00 (from $22.00) while maintaining a Buy rating.
Analyst Robyn Karnauskas sees multiple avenues for upside along with some downside potential due to a potential delay in approval of FL Mut.
The analyst... More
Epizyme (EPZM) PT Lowered to $25 at Oppenheimer on 4Q Report; 'Provides Encouraging Clinical Update'
March 13, 2018 1:21 PM EDTOppenheimer lowered its price target on Epizyme (NASDAQ: EPZM) to $25.00 (from $26.00) while maintaining a Outperform rating, following the company's fourth quarter earnings report.
Analyst Leah Rush Cann notes a reduced price target on the shares, despite EPZM reporting fourth quarter earnings per... More
